Navigation Links
CryoLife Amends Tender Offer Related to its Proposed Acquisition of Cardiogenesis Corporation
Date:4/15/2011

er and Where to Find It

In connection with the potential merger, Cardiogenesis Corporation has filed a preliminary proxy statement with the Securities and Exchange Commission.  Additionally, Cardiogenesis Corporation will file other relevant materials with the Securities and Exchange Commission in connection with the proposed acquisition of Cardiogenesis Corporation by CryoLife, Inc. pursuant to the terms of an Amended and Restated Agreement and Plan of Merger by and among Cardiogenesis Corporation, CryoLife, Inc., and CL Falcon, Inc. a wholly-owned subsidiary of CryoLife, Inc.  The materials filed by Cardiogenesis Corporation with the Securities and Exchange Commission may be obtained free of charge at the Securities and Exchange Commission's web site at www.sec.gov.  Investors and shareholders also may obtain free copies of the proxy statement from Cardiogenesis Corporation by contacting Cardiogenesis Corporation Investor Relations at 11 Musick, Irvine, CA, 92618, telephone number (949) 420-1827 or IR@Cardiogenesis.com.  Investors and security holders of Cardiogenesis Corporation are urged to read the definitive proxy statement and the other relevant materials when they become available before making any voting or investment decision with respect to the proposed merger because they will contain important information about the merger and the parties to the merger.

Cardiogenesis Corporation and its respective directors, executive officers and other members of their management and employees, under the Securities and Exchange Commission rules, may be deemed to be participants in the solicitation of proxies of Cardiogenesis Corporation shareholders in connection with the proposed merger.  Investors and security holders may obtain more detailed information regarding the names, affiliations and interests of certain of Cardiogenesis' executive officers and
'/>"/>

SOURCE CryoLife, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. CryoLife Files Investigational Device Exemption (IDE) to Begin Clinical Trials for PerClot® in the U.S.
2. David P. Lang Appointed Vice President of CryoLife International, Inc.
3. CryoLife to Present at UBS Global Life Sciences Conference
4. CryoLife Receives Humanitarian Use Device Designation for SynerGraft(R) Processed Human Aortic Heart Valves
5. CryoLife to Present at UBS Global Life Sciences Conference
6. CryoLife Announces First Clinical Use of BioFoam(R)
7. CryoLifes Second Annual Surgical Congress for the Ross Procedure to Draw More than 130 Cardiovascular Surgeons from Around the World
8. CryoLife Announces Implants of First FDA-Cleared SynerGraft(R) Processed Human Cardiac Patch Material
9. CryoLife Receives FDA 510(k) Clearance for SynerGraft(R) Processed Human Cardiac Patch Material
10. CryoLife Reports Record First Quarter Revenues of $26.7 Million
11. CryoLife Announces Release Date and Teleconference Call Details for 2009 First Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... and OSAKA, Japan ... Cell Research Application (CiRA) of Kyoto University and ... they will work together to develop clinical applications ... as heart failure, diabetes mellitus, neurological disorders and ... Cell Applications" (T-CiRA) is designed to expedite multiple ...
(Date:4/16/2015)... 2015 Proove Biosciences , Inc. ... BIO Contest for the 2015 BIO International Convention. ... BIO International Convention will take place June 15-18 at ... Buzz of BIO contest, industry leaders will be voting ... the conference. The community voting period began on April ...
(Date:4/16/2015)... OncoTAb, Inc., a University ... company, announced today the appointment of physician and ... Operating Officer (COO). Cooper brings to OncoTAb more ... diagnostic and biotechnology platforms in the fields of ... career transcends the field of medical and scientific ...
(Date:4/16/2015)... 2015  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the ... venture with G-treeBNT (ReGenTree LLC) has retained Ora, ... for the orphan disorder, neurotrophic keratopathy (NK), and ... syndrome (DES) in the U.S.  Both trials will ... year.  Each of these eye disorders was being ...
Breaking Biology Technology:CiRA and Takeda Enter 10-year Collaboration on iPS Cell Research 2CiRA and Takeda Enter 10-year Collaboration on iPS Cell Research 3Proove Bisociences to Participate in the Buzz of BIO at the 2015 BIO International Convention 2Proove Bisociences to Participate in the Buzz of BIO at the 2015 BIO International Convention 3OncoTAb Names Dr. David L. Cooper as COO 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 3RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 4RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 5
... , , SUNNYVALE, Calif., July ... endovascular devices for the treatment of chronic total occlusions (CTOs), today ... Operating Officer. Chris previously held the position of Executive VP, Sales ... in Medical Devices including the last 2 years at FlowCardia. , ...
... LONG BRANCH, N.J., July 23 The 2009 Pharma ... the current 500 attendees and 100 exhibitors have been posted ... Alexay of Apaporis LLC, the event organizer. Attendance is ... 2008,s record turnout. One thousand attendees are expected on ...
... , SEATTLE, July 23 Cell Therapeutics, Inc. (Nasdaq ... of an underwritten public offering of 29,332,107 shares of its common ... common stock at a price to the public of $1.30 per ... common stock, for gross proceeds of approximately $38.1 million. In ...
Cached Biology Technology:FlowCardia, Inc. Appoints Chris Barys to Chief Operating Officer 2ChemOutsourcing Unveils 2009 Attendee List for September Show in New Jersey 2Cell Therapeutics, Inc. Announces Pricing of Public Offering of Common Stock and Warrants 2Cell Therapeutics, Inc. Announces Pricing of Public Offering of Common Stock and Warrants 3
(Date:3/19/2015)... , March 19, 2015  NXT-ID, Inc. (NASDAQ: ... focused on the growing mobile commerce market, announces its biometric ... news clip that aired this week on Washington ... In a segment "The Next Great Thing", host ... new way to pay, and ,a really big breakthrough in ...
(Date:3/17/2015)... , March 17, 2015 MedNet ... specializing in clinical study management systems, is pleased ... attendance at ARENA,s Outsourcing in Clinical Trials Southeast ... event provides an excellent forum for MedNet to ... and affordable software-as-a-service (SaaS) eClinical technology platform. ...
(Date:3/17/2015)... 2015  MecklerMedia Corporation (OTCQX: MECK) announced its ... robots ever held in New York ... 11-13, 2015 at the Javits Convention Center. ... include: Acorn Product Development; Axis NJ; c-Link Systems; ... Littler; NewBotic Corporation; Neya Systems LLC; Reliabotics; RoboKind; ...
Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 2NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 3Connect With MedNet Solutions At Outsourcing In Clinical Trials Southeast 2MecklerMedia's RoboUniverse New York Announces Sponsors and Exhibitors, May 11-13, 2015 2
... crop in states such as Massachusetts, Wisconsin, New Jersey, ... problems for growers trying to realize profits in heavy ... pest damage can have a particularly significant negative impact ... feeding preferences of insects, entomologists have reported that several ...
... , JERUSALEM, ISRAEL, June 22, 2011 Ben-Gurion University ... most comprehensive report to date on Israel,s environmental movement. ... experts and public support, as well as its perilous ... Movement: Trends, Needs and Potential," was presented to Knesset ...
... Evolution is usually thought to be a very ... to adaptive mutations. But environmental change due to things ... very fast. There are just two options for species ... become extinct. So, according to McGill biology professor, ...
Cached Biology News:Pest preferences for cranberry cultivars determined 2Ben-Gurion University team presents environment movement report to Israel's Knesset 2Ben-Gurion University team presents environment movement report to Israel's Knesset 3Evolution to the rescue 2
... for ChIP assays. Efficient fixation of a ... crucial step for the Chromatin-immunoprecipitation (ChIP) technique. ... most important parameter. Two major problems concerning ... into account: first, an excess of crosslinking ...
Mouse monoclonal antibody to ANAPC2 - anaphase promoting complex subunit 2...
Handy 100V Power Supply is Low-cost, compact and lightweight. Easy to operate - either 50 or 100 VDC is selectable as the output voltage. These voltages are sufficient for ordinary electrophoresis....
Rabbit polyclonal to Synapsin II ( Abpromise for all tested applications). entrezGeneID: 6854 SwissProtID: Q92777...
Biology Products: